NEW YORK (GenomeWeb) – Duke University and Tempus are teaming up on a brain cancer research initiative.

Under the terms of the agreement, Tempus will provide sequencing and analysis for glioblastoma patients in a clinical study being conducted at Duke, using an engineered poliovirus for treatment. The trial began in 2012 and was awarded breakthrough status by the US Food and Drug Administration last year. Glioblastoma is a highly aggressive tumor that grows and spread quickly, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.